Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer plans to buy Arena Pharmaceuticals for $6.7 billion

By Brian Buntz | December 13, 2021

Pfizer/ArenaPfizer (NYSE:PFE) plans to spend almost $7 billion to acquire Arena Pharmaceuticals (NSDQ:ARNA). The purchase would bolster its pipeline of immuno-inflammatory drugs. 

ARNA shares surged 80% to $90.08 after the announcement. PFE shares ticked up to $55.20 to 4.57%. 

The transaction was valued at $100 per Arena share in cash. 

The proposal has won the unanimous approval of the boards of directors at both firms. 

Arena’s lead candidate etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, offers promise for several immuno-inflammatory diseases, including Crohn’s disease, atopic dermatitis and ulcerative colitis. Arena also has ongoing Phase 2 trials involving etrasimod in eosinophilic esophagitis and alopecia areata.

Earlier this year, Bristol Myers Squibb won the first gastrointestinal indication of an S1P receptor modulator. Known as ozanimod, the drug was branded as Zeopsia. 

Etrasimod has been the subject of 27 clinical studies to date. 

Other drug candidates in Arena’s pipeline include temanogrel and APD418. Temanogrel is a potential for microvascular obstruction and Raynaud’s phenomenon secondary to systemic sclerosis. APD418 is now in a Phase 2 study for acute heart failure.

Arena is also developing a cannabinoid type-2 receptor known as olorinab for the potential treatment of chronic pain, including visceral pain stemming from gastrointestinal disorders. 

Tell Us What You Think! Cancel reply

Related Articles Read More >

Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio
Dollars for drugs
Democrats’ drug pricing plan attracts pushback from Republicans
GBT/Pfizer
Pfizer to scoop up Global Blood Therapeutics for $5.4 billion 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards